SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(4): 280-283, 2023 04.
Article
in English
| MEDLINE | ID: covidwho-2285171
ABSTRACT
BACKGROUND:
It is unclear which patients with multiple sclerosis (MS) are most susceptible for omicron breakthrough infections.METHODS:
We assessed omicron breakthrough infections in vaccinated patients with MS with and without disease-modifying therapies enrolled in an ongoing large prospective study. We longitudinally studied humoral responses after primary and booster vaccinations and breakthrough infections.RESULTS:
Omicron breakthrough infections were reported in 110/312 (36%) patients with MS, and in 105/110 (96%) infections were mild. Omicron breakthrough infections occurred more frequently in patients treated with anti-CD20 therapies and sphingosine-1 phosphate receptor (S1PR) modulators, patients with impaired humoral responses after primary immunisation (regardless of treatment) and patients without prior SARS-CoV-2 infections. After infection, antibody titres increased in patients on S1PR modulator treatment while anti-CD20 treated patients did not show an increase.CONCLUSIONS:
SARS-COV-2 omicron breakthrough infections are more prevalent in patients with MS on anti-CD20 therapies and S1PR modulators compared with other patients with MS, which correlated with decreased humoral responses after vaccination. Humoral responses after infection were higher in S1PR modulator-treated patients in comparison to patients on anti-CD20 therapies, suggesting that immunological protection from contracting infection or repeated exposures may differ between these therapies.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Sphingosine 1 Phosphate Receptor Modulators
/
COVID-19
/
Multiple Sclerosis
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
J Neurol Neurosurg Psychiatry
Year:
2023
Document Type:
Article
Affiliation country:
Jnnp-2022-330100
Similar
MEDLINE
...
LILACS
LIS